腫瘍抑制因子REIC/Dkk-3によるCD147の発現低下とヒト前立腺癌細胞増殖抑制の関連 by Mori, Akihiro
P rostate cancer is a common disease in the male population of many developed countries,  includ-
ing the United States [1].  In the considerable number of 
cases of significant prostate cancer,  the cancer’s pro-
gression is often accompanied by a decreased quality of 
life,  and death occurs early [1 , 2].  The current thera-
peutic strategies,  including radical prostatectomy,  
androgen deprivation therapy,  radiation,  and cytotoxic 
chemotherapy,  often allow recurrence and fail to stop 
the progression of the disease [2].  Thus,  novel and 
effective therapeutic agents are needed to treat recurrent 
progressive prostate cancer.
CD147 (also known as EMMPRIN) is a cell mem-
brane glycoprotein that was found to be the most fre-
quently upregulated mRNA and protein in metastatic 
cells isolated from the bone marrow of cancer patients 
[3].  The protein is reported to be overexpressed in many 
solid tumors,  including prostate cancer,  indicating a 
key role of CD147 in the processes of tumorigenesis,  
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The cluster of differentiation 147 (CD147),  also known as EMMPRIN,  is a key molecule that promotes cancer 
progression.  We previously developed an adenoviral vector encoding a tumor suppressor REIC/Dkk-3 gene 
(Ad-REIC) for cancer gene therapy.  The therapeutic effects are based on suppressing the growth of cancer cells,  
but,  the underlying molecular mechanism has not been fully clarified.  To elucidate this mechanism,  we inves-
tigated the effects of Ad-REIC on the expression of CD147 in LNCaP prostate cancer cells.  Western blotting 
revealed that the expression of CD147 was significantly suppressed by Ad-REIC.  Ad-REIC also suppressed the 
cell growth of LNCaP cells.  Since other researchers have demonstrated that phosphorylated mitogen-activated 
protein kinases (MAPKs) and c-Myc protein positively regulate the expression of CD147,  we investigated the 
correlation between the CD147 level and the activation of MAPK and c-Myc expression.  Unexpectedly,  no pos-
itive correlation was observed between CD147 and its possible regulators,  suggesting that another signaling 
pathway was involved in the downregulation of CD147.  This is the first study to show the downregulation of 
CD147 by Ad-REIC in prostate cancer cells.  At least some of the therapeutic effects of Ad-REIC may be due to 
the downregulation of the cancer-progression factor,  CD147.
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invasion and metastasis [3-10].  CD147 is highly 
expressed on the surface of cancer cells and stimulates 
adjacent fibroblasts or cancer cells to produce matrix 
metalloproteinases,  facilitating the invasion of the can-
cer cells [3].  The CD147 expression levels of prostate 
cancer patients have been reported to be higher than 
those in their normal counterparts and the elevated 
expression of CD147 is significantly correlated with 
histopathological malignancy,  cancer progression and 
an unfavorable prognosis [4-6].
It was also reported that CD147 stimulates the 
expression of vascular endothelial growth factor and 
hyaluronan,  which leads to angiogenesis,  anchor-
age-independent growth and multidrug resistance [3].  
These findings− based on both clinical studies and basic 
research− clearly indicate that CD147 is an essential 
molecule in cancer progression and is therefore a very 
attractive target for anti-cancer treatment [3].
The reduced expression in immortalized cell (REIC) 
gene is identical to Dickkopf-3 (Dkk-3),  and the 
expression of the REIC/Dkk-3 gene is significantly 
downregulated in a broad range of human cancer cells 
[11-13].  REIC/Dkk-3 is a tumor suppressor gene and is 
thought to be useful for gene therapy for human malig-
nant tumors.  We therefore developed adenoviral vector 
agents encoding a tumor suppressor REIC/Dkk-3 gene 
(Ad-REIC) for cancer gene therapy [12 , 13].  Ad-REIC 
induces cancer cell-specific apoptosis in prostate cancer 
cells [13].
It was reported that the induction of apoptosis is 
dependent on the activation of c-Jun-NH2-kinase 
(JNK) by cellular endoplasmic reticulum (ER) stress 
signaling [12 , 13].  Accumulating evidence indicates 
that the therapeutic effects of Ad-REIC are based on the 
induction of apoptosis,  the suppression of cell growth 
and the inhibition of invasion in various cancer cell 
types [11-13].  However,  the molecular mechanism 
underlying the therapeutic effects of Ad-REIC has not 
been fully clarified.
CD147 is a key molecule that promotes cancer cell 
growth,  invasion and metastasis [3-10].  To elucidate 
the molecular mechanism of Ad-REIC-based gene ther-
apy,  we investigated the effects of Ad-REIC treatment 
on the expression of CD147 and other molecules in 
prostate cancer cells.
Materials and Methods
Cells and cell culture. Three Human prostate 
cancer cell lines (PC-3,  LNCaP,  and Du145) and a cer-
vical cancer cell line (HeLa) were obtained from the 
American Type Culture Collection (Rockville,  MD,  
USA).  A mouse prostate cancer cell line (RM9) was 
kindly provided by Professor T.C.  Thompson (The 
University of Texas,  M.D.  Anderson Cancer Center,  
Houston,  TX,  USA).  The cells were grown in RPMI-
1640 medium (Sigma,  St. Louis,  MO,  USA) or in 
Dulbecco’s modified Eagle’s medium (DMEM;  
Invitrogen,  Carlsbad,  CA,  USA) supplemented with 
10% (v/v) fetal bovine serum (FBS),  penicillin (100 IU/
ml),  and streptomycin (100 μg/ml).  Human normal 
prostate epithelial cells (PrEC) were purchased from 
Lonza (Basel,  Switzerland) and cultivated using the 
medium recommended by the supplier [13].
The generation and expansion of adenoviral vectors 
carrying REIC/Dkk-3 (Ad-REIC). For the develop-
ment of the Ad-REIC vectors,  pShuttle-SGE-REIC 
plasmids were digested with the restriction enzymes 
I-CeuI and PI-SceI and inserted into the Adeno-X Viral 
DNA (Clontech Laboratories,  Mountain View,  CA,  
USA),  as described [14 , 15].  Briefly,  the recombinant 
adenoviral DNA with the full-length human REIC/
Dkk-3 gene was linearized by digestion with PacI and 
transfected into HEK293 cells.  At 7-10 days after trans-
fection,  the HEK293 cells were harvested,  and a viral 
solution was obtained by 3 freeze/thaw cycles.  The 
recovered virus solution was used to propagate suffi-
cient viruses in HEK293 cells for further studies.  All of 
the virus particles were purified by CsCl density gradi-
ent ultracentrifugation and stored at −80˚C.
An adenovirus vector carrying the LacZ gene 
(Ad-LacZ) was used as a control,  as described [13 , 14].  
The adenoviral vectors were produced using replica-
tion-defective adenoviruses of serotype 5.
Western blotting. Western blotting was con-
ducted as described [11 , 14 , 15].  The cells were seeded 
in flat-bottom six-well plates,  cultured for 24 h in com-
plete medium and then sampled.  In the other experi-
ments,  LNCaP cells(5.0 × 105 cells) were treated with 
Ad-LacZ or Ad-REIC at 100 multiplicity of infection 
(MOI) in 0.5 ml of complete medium for 1 h.  Then,  
1.5 ml of fresh medium was added and the cells were 
cultured for 24 h.  The floating dead cells were elimi-
nated and the attached cells were lysed with lysis buffer 
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on ice.  After the insoluble fragments were removed by 
centrifugation,  the extracted proteins were separated on 
a 7.5% SDS-PAGE gel and transferred onto a polyvi-
nylidene fluoride membrane (PVDF membranes; Mil-
lipore,  Billerica,  MA,  USA).
Following the transfer,  the PVDF membranes were 
blocked for 1 h with 5% nonfat milk powder,  6% gly-
cine and 0.1% Tween-20 in Tris buffered saline (TBS).  
The membranes were incubated for 1 h at room tem-
perature with the primary antibodies ; CD147 
(EPR4052,  abcam,  Cambridge,  UK),  REIC/Dkk-3 
(mouse monoclonal,  raised in our laboratory),  and the 
following antibodies from Cell Signaling Technology 
(Danvers,  MA): Phospho-p38 MAPK (cat.#4511),  
Phospho-p44/42 MAPK (Erk1/2) (#4370),  Phospho-
JNK (#9251),  Phospho-c-Jun (#2361),  c-Myc (#9402),  
Phospho-GSK-3β (#9323) and β-Actin (#4967).  After 
three washes in TBS supplemented with 0.1% Tween-
20,  the membranes were incubated with horseradish 
peroxidase-conjugated secondary antibody for 1 h at 
room temperature.  The bound antibodies were visual-
ized by the enhanced chemiluminescence detection 
method (ECL kit,  Amersham Pharmacia Biotech,  
Chandler,  AZ,  USA) using medical X-ray film [11].
The in vitro cell growth assay. LNCaP human 
prostate cancer cells (5.0 × 105 cells) were seeded in 
flat-bottom six-well plates and cultured for 24 h.  The 
cells were treated with Ad-LacZ or Ad-REIC at 100 
MOI in 0.5 ml of complete medium for 1 h,  and 1.5 ml 
of fresh medium was then added and the cells were 
incubated for 24 h.  Following the elimination of float-
ing dead cells by medium exchange,  the attached cells 
were detached by trypsin.  The number of cells was then 
determined with a disposable hemocytometer.
Statistical analysis. The data are shown as the 
mean ± standard deviation.  The unpaired Student’s 
t-test was used to analyze the significance of differences 
between pairs of groups.  P-values < 0.05 were consid-
ered significant.
Results
The expression of CD147 in normal prostate epithe-
lial cells and prostate cancer cells. We examined the 
expression of CD147 protein in prostate - derived cells 
including human normal prostate epithelial cells 
(PrEC).  The CD147 antibody used was confirmed to 
react with both human and mouse CD147 protein in 
our preliminary studies.  Three bands of CD147 protein 
were observed at the molecular size of 40-60 kDa 
(Fig. 1); this is consistent with previous reports,  which 
stated that the protein indicates plural bands of different 
molecular sizes [3].  Relatively strong CD147 expression 
was observed in the LNCaP cancer cells and weak 
expression was detected in the PC-3,  Du145 and HeLa 
cells (Fig. 1).  The expression level in the PrEC and 
mouse prostate cancer RM9 cells was undetectable or 
minimal.
Ad-REIC treatment suppressesed the CD147 
expression in human prostate cancer LNCaP cells.
We used Western blotting to determine the expression 
of CD147 protein in the LNCAp cells after Ad-REIC 
treatment (Fig. 2).  The infectious efficiency of Ad-REIC 
was confirmed to be nearly 100% in our preliminary 
studies.  REIC/Dkk-3 protein was strongly expressed 
after Ad-REIC treatment,  and the bands were recog-
nized at molecular sizes of 60-70 kDa.  The CD147 
expression in the LNCaP cells that underwent the con-
trol treatment was significantly downregulated by 
Ad-REIC.
Ad-REIC significantly inhibited the cell growth of 
LNCaP prostate cancer cells. To investigate the 
anti-proliferative effects of Ad-REIC,  we treated the 
cultured LNCaP cell with the agent.  Apoptosis was sig-
nificantly induced in the Ad-REIC-treated cells com-
pared to the controls.  After the floating dead cells were 
removed,  the attached viable cells were counted for the 
in vitro cell growth assay.  The results showed that the 
number of viable cells was significantly reduced by 
Ad-REIC treatment compared to the controls (Fig. 3).  
The results indicate that the Ad-REIC agent significantly 
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Fig. 1　 The expression of CD147 in human and mouse prostate 
cancer cells as determined by Western blotting.  Human normal 
prostate epithelial cells (PrEC) and the prostate cancer cell lines 
were examined.  The β-actin band is shown as a loading control.
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Fig. 3　 The suppression of cell growth in LNCaP cells with 
Ad-REIC treatment.  The cells were treated with Ad-LacZ or 
Ad-REIC at 100 MOI in 0.5 ml of complete medium for 1 h,  
and then 1.5 ml of fresh medium was added and the cells 
were cultured for 24 h.  The appearance of the cells after 
treatment is shown by phase contrast microscopy (upper 
panel).  The bar graph shows the number of cells in each 
treatment (lower panel).  The data were obtained by ﬁve mea-
surements.  There was a signiﬁcant diﬀerence (＊p＜0.05) 
between the Ad-REIC and Ad-LacZ treatments.
Fig. 2　 The Ad-REIC treatment suppressed the expression of CD147 in 
human prostate cancer LNCaP cells.  The cells were treated with Ad-LacZ or 
Ad-REIC at 100 MOI in 0.5 ml of complete medium for 1 h,  and then 1.5 ml 
of fresh medium was added and the cells were cultured for 24 h.  The 
expression levels of REIC/Dkk-3 and CD147 were analyzed by Western blot-
ting.  The β-actin band is shown as a loading control.
inhibited the cell growth of the prostate cancer cells.
Ad-REIC suppressed the expression of CD147 in a 
MAPK signaling- and c-Myc-independent manner.
With regard to the expression of the CD147 gene,  some 
signaling pathways are reported to affect or regulate its 
transcription [16-19].  Since the expression of CD147 is 
positively controlled by p38-,  Erk1/2- and JNK-
dependent MAPK signaling and the c-Myc protein 
transcription factor [16-19],  we investigated the associ-
ation between the CD147 expression level and the levels 
of phosphorylated MAPKs or c-Myc after Ad-REIC 
treatment.  We also focused on the levels of phosphory-
lated JNK and its downstream molecule,  phosphory-
lated c-Jun,  because the JNK-dependent signaling that 
occurs via these proteins is considered to be an import-
ant step in the induction of apoptosis by Ad-REIC 
[4 , 5].  We used Western blotting to compare the 
expression levels of the indicated factors between 
Ad-LacZ and Ad-REIC treatment (Fig. 4).
The LNCaP cells were confirmed to express the 
REIC/Dkk-3 protein following Ad-REIC treatment.  
Unexpectedly,  no positive association was observed 
between the expression of CD147 and the possible 
CD147 regulators of MAPK signaling and c-Myc 
expression.  We also examined the levels of phosphory-
lated GSK-3β,  a protein regulated by the c-Myc signal-
ing,  but no positive associations was observed between 
the expression and the downregulation of CD147.  As 
for phosphorylated p38,  MAPK signaling was notice-
ably upregulated after Ad-REIC treatment,  indicating 
that the intrinsic cell survival response against the agent 
induced apoptotic signaling.
These findings indicated that the Ad-REIC agent 
downregulates the expression of CD147 without inhib-
iting MAPK signaling or suppressing c-Myc.  In addi-
tion,  no increases in JNK or c-Jun phosphorylation 
were observed with Ad REIC treatment,  indicating that 
JNK signaling had not been significantly activated in the 
LNCaP prostate cancer cells.
Discussion
Accumulating evidence supports the concept that 
CD147 protein is a key player in the development and 
progression of cancer,  including its proliferation,  inva-
sion and metastasis [3-10].  Several research groups 
have proposed that CD147 serves as an important regu-
lator of cell proliferation by promoting the reprogram-
ming of glucose metabolism,  including glycolysis [20-
24].  Glucose provides the precursors for the chemical 
constituents that are required to build the macromole-
cules that are essential for cell division and proliferation 
[22].  Thus,  the downregulation or blocking of CD147 
can robustly reduce glycolysis,  and the targeting of 
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Fig. 4　 The expression levels of the factors that may be respon-
sible for the expression of CD147 were investigated after Ad-REIC 
treatment.  Because the expression of CD147 is reported to be 
positively regulated by p38-,  Erk1/2- and JNK-dependent MAPK 
signaling and the expression of c-Myc,  we analyzed the levels of 
these related factors by Western blotting.  The cells were treated 
with Ad-LacZ or Ad-REIC at 100 MOI in 0.5 ml of complete medium 
for 1 h,  and then 1.5 ml of fresh medium was added and the cells 
were cultured for 24 h.  The β-actin band is shown as a loading 
control.  P-: phosphorylated.
CD147 using pharmacological agents could be an 
attractive cancer therapeutic strategy [22 , 23 , 25-27].
The result of the resent study revealed the suppres-
sive effects of Ad-REIC treatment on CD147,  a can-
cer-progression factor,  and on the cell growth of pros-
tate cancer LNCaP cells.  This is the first study to 
indicate a link between the downregulation of CD147 
and the therapeutic effects of the Ad-REIC agents.
REIC/Dkk-3 has emerged as a novel tumor suppres-
sor in the development and progression of cancer.  Its 
abundant expression in normal tissues is frequently 
abolished in solid cancer types and hematological 
malignancies due to epigenetic suppression with aber-
rant promoter methylation [28].  The Ad-REIC agents 
reduced the tumor volume of prostate cancer PC-3 and 
malignant mesothelioma 211H xenografts in nude 
mouse models,  and this was attributed to the activation 
of JNK with its phosphorylation leading to the induc-
tion of apoptosis [12 , 13 , 28].  We therefore examined 
the levels of phosphorylated JNK and c-Jun in the pres-
ent study; however,  no significant change was 
observed in the prostate cancer LNCaP cells after 
Ad-REIC treatment.
The induction of apoptosis and the suppression of 
cell growth was indeed observed in the LNCaP cells 
after treatment with Ad-REIC agents,  indicating that 
the JNK activation pathway might not be used for the 
anti-proliferative signaling in some cancer cell lines.  
These results suggest that other anti-cancer mechanisms 
are involved in the effects of Ad-REIC agents and that 
the downregulation of CD147 could be an important 
therapeutic effect of these agents.
The original Ad-REIC agent of GMP (Good 
Manufacturing Practice) was evaluated in a phase I/IIa 
trial of in situ gene therapy for patients with prostate 
cancer [29].  Patients with high-risk localized prostate 
cancer were enrolled,  and the inhibitory effects against 
cancer recurrence after radical prostatectomy were 
assessed.  The continuous induction of apoptosis was 
reported in Ad-REIC-injected lesions,  and an apparent 
reduction of the tumor volume was observed in some 
patients.  A significantly favorable outcome was 
observed,  with respect to biochemical recurrence-free 
survival,  in the higher-dose treatment groups com-
pared to the lower-dose groups.  The results of the pres-
ent study suggest that the therapeutic effects observed in 
the above trial’s patients may at least partially depend on 
the suppression of the CD147 oncoprotein by Ad-REIC.  
Further studies using cancer-bearing mouse models are 
necessary to investigate the Ad-REIC mediated down-
regulation of CD147 in vivo.
Although the tight association between CD147 and 
tumorigenesis has recently been a topic of focus,  the 
signaling pathway by which the expression of CD147 is 
regulated has not been fully elucidated.  In a coculture 
experiment involving MCF-7 breast cancer cells and 
macrophages,  CD147 was upregulated in cocultured 
cancer cells in a JNK- and NF-κB-dependent man-
ner; this led to the increased invasive capacity of the 
cancer cells [16].  Other researchers investigated the role 
of the MAPK signaling pathway in the downregulation 
of CD147 that was induced by a plant compound in 
PMA (Phrbol 12-myristate 13-acetate)-induced THP-1 
cells.  They demonstrated that the agent inhibited the 
expression of CD147 through the inhibition of both 
ERK1/2 and p38 MAPK signaling pathways [17].
As for the MAPK signaling-dependent expression of 
CD147,  it was also reported that a selective inhibitor of 
COX 2 induced the expression of CD147 via the activa-
tion of p38,  which promoted the invasion of PANC-1 
pancreatic cancer cells [18].  In terms of the transcrip-
tion of the CD147 gene,  the mechanisms and roles of 
c-Myc protein in the expression of CD147 were inten-
sively investigated in human breast cancer cells.  The 
CD147 core promoter region for transcription fac-
tor-binding sites was examined and binding sites for 
c-Myc were identified in this 217-bp region [19].  It was 
suggested that c-Myc could bind to the special binding 
motif of the promoter region to activate the transcrip-
tion of CD147 [19].  In the present study,  we investi-
gated the involvement of the MAPK signaling pathway 
and c-Myc protein in the downregulation of CD147,  
and we did not observe the expected association 
between the currently examined signaling pathways and 
the downregulation of CD147 (Fig. 5).  It is conceivable 
that another type of signaling is involved in the down-
regulation that was induced by treatment with 
Ad-REIC.
In conclusion,  our findings suggest that a novel 
therapeutic mechanism is involved in the effects of 
Ad-REIC.  The suppression of the CD147 oncoprotein 
could be an important action of the agent in addition to 
the previously reported JNK phosphorylation that 
occurs via ER stress signaling.  Based on the significance 
of CD147 in the progression of cancer,  the further elu-
cidation of the signaling pathway that regulates the 
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expression of CD147 can be expected to make this mol-
ecule a more attractive therapeutic target.
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